Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | RAB9A | P51151 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.56 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.53 |
| ▸ | FEN1 | P39748 | 1/20 | 0.53 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL276676 | 0.88 | NR4A2 (0.65) | SMN1; SMN2RAB9ALMNAFFAR1CYP1A2 | |
| SCHEMBL19043116 | 0.86 | HDAC8 (0.63) | SMN1; SMN2RAB9ALMNAFFAR1CYP1A2 | |
| SCHEMBL27871457 | 0.84 | SMN1; SMN2 (0.62) | SMN1; SMN2RAB9ALMNAFFAR1CYP1A2 | |
| Fenbufen SCHEMBL11329267 | 0.82 | SMN1; SMN2 (1.00) | SMN1; SMN2RAB9ALMNAFFAR1CYP1A2 | |
| Fenbufen SCHEMBL25117 | 0.82 | SMN1; SMN2 (1.00) | SMN1; SMN2RAB9ALMNAFFAR1CYP1A2 | |
| SCHEMBL8534233 | 0.82 | SMN1; SMN2 (0.84) | SMN1; SMN2RAB9ALMNAFFAR1CYP1A2 | |
| Fenbufen SCHEMBL11393779 | 0.81 | SMN1; SMN2 (0.96) | SMN1; SMN2RAB9ALMNAFFAR1CYP1A2 | |
| SCHEMBL7590043 | 0.81 | SMN1; SMN2 (0.63) | SMN1; SMN2RAB9ALMNAFFAR1CYP1A2 | |
| SCHEMBL19043378 | 0.81 | MMP1 (0.60) | SMN1; SMN2RAB9ALMNAFFAR1L3MBTL1 | |
| Biphenyl SCHEMBL28382562 | 0.80 | FFAR1 (0.57) | SMN1; SMN2RAB9ALMNAFFAR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114605316-A | Beta-aromatic heterocyclic-gamma-trifluoromethyl amine compound and synthesis method thereof | 中山大学 | 2022-06-10 | — | — | CN | claimed |
| CN-114605316-A | Beta-aromatic heterocyclic-gamma-trifluoromethyl amine compound and synthesis method thereof | 中山大学 | 2022-06-10 | — | — | CN | disclosed |
| EP-1280764-B1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2010-11-24 | — | — | EP | disclosed |
| US-20090181971-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. | 2009-07-16 | — | — | US | disclosed |
| US-20090181971-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. | 2009-07-16 | — | — | US | disclosed |
| US-20090181971-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. | 2009-07-16 | — | — | US | disclosed |
| US-7288567-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2007-10-30 | — | — | US | disclosed |
| US-7288567-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2007-10-30 | — | — | US | disclosed |
| US-7288567-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2007-10-30 | — | — | US | disclosed |
| EP-1524262-A1 | Inhibitors of histone deacetylase | Methylgene, Inc. (CA) | 2005-04-20 | — | — | EP | disclosed |
| EP-1421071-A2 | SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS | NOVO NORDISK A/S (DK) | 2004-05-26 | — | — | EP | disclosed |
| EP-1280764-A2 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2003-02-05 | — | — | EP | disclosed |
| WO-2003004480-A2 | SUBSTITUTED PIPERAZINE AND DIAZEPANES AS HISTAMINE H3 RECEPTOR AGONISTS | NOVO NORDISK A/S (DK) | 2003-01-16 | — | — | WO | disclosed |
| US-20020115826-A1 | Inhibitors of histone deacetylase | 92229129 QUEBEC INC. (CA) | 2002-08-22 | — | — | US | disclosed |
| WO-2001070675-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115826-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC3 | SMN1; SMN2 3671/4885RAB9A 2909/4885LMNA 1922/4885 |
| US-20090181971-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | SMN1; SMN2 3671/4885RAB9A 2909/4885LMNA 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.